Literature DB >> 16979597

Mice lacking the gene encoding for MMP-9 and resistance artery reactivity.

Jun Su1, Desiree I Palen, Pamela A Lucchesi, Khalid Matrougui.   

Abstract

OBJECTIVES: To define the link between the deletion of gene encoding for metalloproteinase 9 and resistance artery reactivity, we studied in vitro smooth muscle and endothelial cell function in response to pressure, shear stress, and pharmacological agents.
BACKGROUND: Matrix metalloproteinases play a crucial role in the regulation of extracellular matrix turnover and structural artery wall remodeling.
METHODS: Resistance arteries were isolated from mice lacking gene encoding for MMP-9 (KO) and their control (WT). Hemodynamic, pharmacology approaches, and Western blot analysis were used in this study.
RESULTS: The measurement of blood pressure in vivo was similar in KO and WT mice. Pressure-induced myogenic tone, contractions to angiotensin-II and phenylephrine were similar in both groups. The inhibition of MMP2/9 ((2R)-2-[(4-biphenylylsulfonyl) amino]-3-phenylpropionic acid) significantly decreased myogenic tone in WT and had no effect in KO mice. Relaxation endothelium-dependent (flow-induced- dilation 41.3+/-0.6 vs. 21+/-1.6 at 10 microl/min in KO and WT mice, respectively, P<0.05) and eNOS expression were increased in KO compared to WT mice. The inhibition of eNOS with L-NAME significantly decreased endothelium response to shear stress, which was more pronounced in KO mice resistance arteries (-26.83+/-2.5 vs. -15.84+/-2.3 at 10 microl/min in KO and WT, respectively, P<0.05). However, the relaxation to exogenous nitric oxide-donor was similar in both groups.
CONCLUSION: Our study provides evidence of a selective effect of MMP-9 on endothelium function. Thus, MMP-9 gene deletion specifically increased resistance artery dilation endothelium-dependent and eNOS expression. Based on our results, MMP-9 could be a potential therapeutic target in cardiovascular disease associated with resistance arteries dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979597     DOI: 10.1016/j.bbrc.2006.08.189

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Vascular receptors as new substrates for matrix metalloproteinases in hypertension and other inflammatory states.

Authors:  Theodore J Kalogeris; Ronald J Korthuis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-16       Impact factor: 4.733

Review 2.  Mechanisms of I/R-Induced Endothelium-Dependent Vasodilator Dysfunction.

Authors:  Ronald J Korthuis
Journal:  Adv Pharmacol       Date:  2017-12-08

3.  Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats.

Authors:  Stephen F Rodrigues; Edward D Tran; Zuleica B Fortes; Geert W Schmid-Schönbein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

4.  Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.

Authors:  Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-28       Impact factor: 3.619

Review 5.  Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature.

Authors:  A K Chow; J Cena; R Schulz
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 6.  Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations.

Authors:  Alejandro F Prado; Rose I M Batista; Jose E Tanus-Santos; Raquel F Gerlach
Journal:  Biomolecules       Date:  2021-04-16

7.  Assessment of the concentration of selected metalloproteinases (MMP-2, MMP-3, MMP-9 and MMP-13) in patients with ulcers as a complication of type 2 diabetes.

Authors:  Daria Kupczyk; Rafał Bilski; Renata Studziñska; Alina Woźniak
Journal:  Postepy Dermatol Alergol       Date:  2020-11-13       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.